GENIX PHARMACEUTICALS CORP (GENX.CA) Stock Income Statement
TSX-V:GENX - TSX Venture Exchange - CA37232A1093 - Common Stock - Currency: CAD
| 2024 (2024-10-31) | 2023 (2023-10-31) | 2022 (2022-10-31) | 2021 (2021-10-31) | 2020 (2020-10-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.10K | 12.40K | 0.00 | 0.00 | 0.00 | |||
| Cost Of Goods | 2.80K | 9.10K | N/A | N/A | 0.00 | |||
| Gross Profit | 1.30K | 3.30K | N/A | N/A | 0.00 | |||
| Operating Expenses | 243.50K | 885.50K | 1.03M | 1.66M | 715.70K | |||
| Selling, General, and Administrative Expenses | 241.20K | 336.70K | 467.00K | 1.12M | 353.60K | |||
| Operating Income | -242.20K | -882.20K | -1.03M | -1.66M | -715.70K | |||
| Interest Income/Expense | -121.10K | -56.50K | -41.40K | 3.90K | -3.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | 290.20K | -3.46M | N/A | N/A | N/A | |||
| Income Before Taxes | -73.20K | -4.40M | -1.07M | -1.65M | -718.70K | |||
| Net Income | -73.20K | -4.40M | -1.07M | -1.65M | -718.70K | |||
| EBITDA | -241.10K | -334.80K | -468.40K | -1.12M | -354.10K | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.00 | -0.07 | -0.02 | -0.03 | -0.01 | |||
| Statistics | ||||||||
| Gross Profit Margin | 31.71% | 26.61% | N/A | N/A | N/A | |||
| Profit Margin | -1785.37% | -35448.39% | N/A | N/A | N/A | |||
| Operating Profit Margin | -5907.32% | -7114.52% | N/A | N/A | N/A | |||
All data in CAD